- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02763527
Effectiveness of Negotiating Self-determination to Reduce Cigarette Consumption
The Effectiveness of Negotiating Self-Determination to Reduce Cigarette Consumption (NSD-RCC) Among Smokers Attending Outpatient Clinics: A Cluster Randomized Controlled Trial
Background: Smokers attended to outpatient clinics present an excellent 'teachable moment' for smoking cessation interventions. This protocol paper describes the rationale and methods of a large randomized controlled trial which aims to evaluate the effectiveness of negotiating self-determination to reduce cigarette consumption among smokers attending outpatient clinics
Methods: A randomized controlled trial will be conducted in 10 out-patient clinics in Hong Kong. Subjects in the intervention group will receive a brief intervention on smoking reduction plus a smoking reduction leaflet. Additionally, subjects will be asked to think about a smoking reduction schedule for themselves after the negotiation with the counsellor. Subjects in the control group will receive a brief advice on quitting plus a leaflet on smoking cessation. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted. The primary outcome measure is biochemically validated abstinence at 6 months. Secondary outcomes are: (i) biochemically validated abstinence at 12 months, (ii) self-reported 7-day point prevalence of abstinence at 6 and 12 months, (iii) self-reported reduction of ≥ 50% in cigarette consumption at 6 and 12 months, and (iv) self-efficacy against tobacco at 6 and 12 months.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This study aims to test the effectiveness of negotiating self-determination to reduce cigarette consumption (NSD-RCC) among smokers attending outpatient clinics.
Intervention Group (QP) Subjects in this group will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet (the content will include a roadmap of smoking reduction strategy and information on how to cope with nicotine withdrawal symptoms). The whole intervention will last about 1 minute or slightly longer if necessary. In addition, subjects will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a "booster" intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target.
Control Group (QI) Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and "booster" intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group.
Data collection
After completing the baseline questionnaire, subjects will receive proposed intervention according to their group assignment. Four consecutive follow-ups (at 1, 3, 6 and 12 months) will be conducted over the telephone by trained interviewers. Interviewers will first carry out outcome assessments with blinding to group status. Then, the group status will be disclosed so that the intervention group will receive the booster intervention and the control group will not. Smokers who have successfully quit smoking at 6-month will be invited to come back to the out-patient clinic and have biochemical validation tests (saliva cotinine test and exhaled CO test).
Analysis Data analysis will be performed using the Statistical Package for Social Science. We will compare the baseline characteristics of the participants by chi-square test for categorical variables and F-test for continuous variables between the intervention and the control group. We shall use the chi-square test to assess the effect of intervention and calculate the crude odds ratio (OR) with 95% confidence interval (CI) for the primary and secondary outcomes. Those who are lost to follow-up or refuse to participate in the validation tests, will be treated as smokers with no reduction in cigarette consumption compared with (a) baseline, as the main analysis (by intention to treat), (b) the most recent level and (c) complete case (per protocol) analysis by excluding subjects with missing data as a sensitivity analysis.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: William, Ho Cheung LI, PhD
- Telefonní číslo: 39176634
- E-mail: william3@hku.hk
Studijní záloha kontaktů
- Jméno: Ka Yan, HO Ho, MPhil
- Telefonní číslo: 39176328
- E-mail: devilbb@hku.hk
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
smokers
- who are Chinese
- aged 18 years or above
- who smoke at least two cigarettes per day
- with moderate to severe nicotine dependence, and
- have no intention to quit smoking ≤7 days, but are interested in reducing the number of cigarettes smoked per day .
Exclusion Criteria:
smokers
- with unstable medical conditions as advised by the doctor in charge,
- with poor cognitive state or mental illness,
- who participate in other smoking cessation programmes or services,
- with mild nicotine dependence, or
- who claim that they can quit ≤7 days
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Smoking reduction
Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet.
They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor.
The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level.
For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a "booster" intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target.
Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers.
|
A brief intervention on smoking reduction plus a smoking reduction leaflet
|
|
Komparátor placeba: Smoking Cessation
Subjects in the QI group will always be advised to quit immediately rather than to quit progressively.
Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group.
In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH).
Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and "booster" intervention during telephone follow-ups.
However, they will undergo a similar schedule of telephone follow-up as those in the QP group.
|
A brief advice on quitting plus a leaflet on smoking cessation
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
biochemically validated abstinence using exhaled CO test
Časové okno: 6 months
|
6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
biochemicky ověřená abstinence pomocí testu na CO
Časové okno: 12 měsíců
|
12 měsíců
|
|
|
sami hlásili 7denní bodovou prevalenci abstinence
Časové okno: 6 měsíců
|
6 měsíců
|
|
|
sami hlásili 7denní bodovou prevalenci abstinence
Časové okno: 12 měsíců
|
12 měsíců
|
|
|
sami uvádějící snížení spotřeby cigaret o ≥ 50 %.
Časové okno: 6 měsíců
|
6 měsíců
|
|
|
sami uvádějící snížení spotřeby cigaret o ≥ 50 %.
Časové okno: 12 měsíců
|
12 měsíců
|
|
|
self-efficacy against tobacco
Časové okno: 6 months
|
Subjects' self-efficacy against tobacco was assessed by using 12-item Smoking Self-efficacy Questionnaire (SEQ-12).
SEQ-12 is a valid and reliable scale, which has been used in both research and clinical setting.
|
6 months
|
|
self-efficacy against tobacco
Časové okno: 12 months
|
Subjects' self-efficacy against tobacco was assessed by using 12-item Smoking Self-efficacy Questionnaire (SEQ-12).
SEQ-12 is a valid and reliable scale, which has been used in both research and clinical setting.
|
12 months
|
|
biochemically validated abstinence using saliva cotinine test
Časové okno: 6 months
|
6 months
|
|
|
biochemically validated abstinence using saliva cotinine test
Časové okno: 12 months
|
12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: William, Ho Cheung LI, PhD, The University of Hong Kong
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Očekávaný)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- GRF
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .